Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft
NCT02878694Phase 3Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of myoblast autologous graft in oculopharyngeal muscular dystrophy (OPMD), ptosis, sponsored by CHU Caen Normandie. Started Nov 2019; status: terminated.
02
Drugs
myoblast autologous graft
03
Conditions
oculopharyngeal muscular dystrophy (OPMD)ptosis
Beyond the preview
Go deeper on NCT02878694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878694.